FILE PHOTO: Teva Pharmaceutical Industries logo appears during a press conference to discuss the company's 201
JERUSALEM (Reuters) – Teva Pharmaceutical Industries & # 39; Chief Financial Officer on Sunday pointed out that the company has not done anything wrong in the wake of a pricing lawsuit filed by 44 US states.
Mike McClellan told a conference in Israel that the suit was a changed and not new, while emphasizing that it was civil and not criminal.
"There have been no developments in this area," he said. "We take these charges seriously and we should defend ourselves."
The Israeli company US unit and 19 other drug companies conspired to divide the drug market to avoid competing and in some cases conspired to prevent the release or raising of the drugs, the complaint filed on Friday in the US District Court in Connecticut.
The prosecutors said Teva Pharmaceuticals USA Inc had orchestrated to inflate drug prices – sometimes by over 1000% – and stifle the competition for generic drugs.
"The claims in this new complaint and in the trial more generally are just that – the claims," Teva said in a statement.
"Teva continues to review the problem internally and has not engaged in any conduct that would lead to civil or criminal liability."
Teva's Tel Aviv-listed shares were down to almost 11 per cent in afternoon trading.
Reporting by Steven Scheer; Editing by Elaine Hardcastle